Adena Robertson
DVM, Medical Director: 4 Paws Pet Hospital
“As a veterinarian, I see nutrition as a core component to overall animal health. I believe this company provides a valuable step that has been largely ignored.”
Reasons for Continued Success
- Experienced team, including PhD veterinarians with advanced expertise in nutrition and cancer care
- Morgan Stanley Research puts the US Pet Industry at $275 billion by 2030, a 2.5x increase in revenue; food and veterinary care are the two largest categories
- In 2020, $42 billion was spent on pet food and treats in the U.S. alone
- CEO is the founder of 2 pet food companies
- On the formulary of one veterinary hospital group (40+ locations)
- Have been approved by the Clinical Advisory Board of a 2nd hospital chain
- 1,800+ total veterinarians in network
- ~160 of whom are oncologists
- Available in 28 states
- North Carolina State and Oregon State's Colleges of Veterinary Medicine are actively referring clients to Canine Biologics' Integrated Nutrition System
- Purdue University’s College of Veterinary Medicine is currently evaluating our products
- 2 additional major veterinary medicine schools currently evaluating our products
- 4 consecutive quarters of positive revenue growth since entering the market (October 2020-September 2021)
- Our product roadmap includes:
- Additional recipes
- Formulated treats
- Tumor-specific supplements
- Liquid diet system for dogs requiring tube feeding
Introduction
Sadly, around 6 million dogs develop cancer every year in the U.S. and Canada [1]. Canine Biologics offers the optimal nutrition they need for their best quality of life. Pet parents and veterinarians finally have an enhanced, integrated solution specifically designed to help their best furry friend battle cancer.
The diagnosis is devastating, but it doesn’t have to mean that a dog’s best days are over. Canine Biologics was founded because we believe that dogs with cancer can, with the proper support, continue to have the energy and vitality to run, play, and love as they always have as they battle this devastating disease.
Veterinarian Testimonials
Esther Chon
DVM, DACVIM (Oncology)
“Canine Biologics offers a great supportive dietary option for our cancer patients. Their customer service is exceptional, making the whole process easy for both the clinician and pet parents. They truly care about their product and for enhancing the lives of veterinary cancer patients.”
Problem
An estimated 500,000 dogs per month develop cancer in North America [2]. Current diet options in the market are extremely limited, specifically when it comes to nutrition formulated to support dogs battling cancer. Pet food companies exhibit little product development or marketing in the highly specific, acutely-felt cancer space.
- Nutrition is increasingly recognized as critical to optimal health outcomes.
- Veterinarians have limited viable recommendations.
- Pet parents increasingly want the best nutrition for their dogs.
Solution
We believe that enhanced nutrition to support dogs battling cancer was severely lacking before Canine Biologics. We are dedicated exclusively to developing nutrition systems designed to support these dogs in the fight of their lives.
Our team of nutrition and oncology-focused, PhD-degreed veterinarians and scientists have taken an evidence-based approach to develop our three-part Integrated Nutrition System, a cross-balanced product and plan to meet each dog’s specific needs.
This includes:
- 100% Human-Grade Food
- Specialized Supplements + Vitamins & Minerals
- Wild-Caught Salmon Oil (Omega-3 Fatty Acids)
We developed this approach based on dozens of peer-reviewed research studies and clinical trials; formulating the nutrition required to support the digestive, immune, and other physiologic systems of dogs fighting cancer.
The science behind our approach is complex, but the results are simple.
- We aim to enhance the absorption of nutrients to maintain weight and muscle mass.
- Improved quality of life for the dog.
- May make cancer treatments more effective.
New Products
We’re in the process of developing specially formulated dog treats to complement our existing nutrition system, additional recipes with alternate proteins, tumor-type specific supplements and a liquid diet system for dogs who require tube feeding.
Our significant product roadmap aims to help dogs with cancer in many new ways!
Business Model
Order types include:
- Sample Packs (Projected release of September, 2021)
- Starter Kits
- Monthly Subscriptions
- Monthly One-time Purchase
We have had three consecutive quarters of positive revenue growth since entering the market (October 2020-June 2021) and we hope to make that four straight quarters very soon!
“Thank you, Canine Biologics, for creating a nutritious and balanced program for Missy. She sure does love the food”
- Happy pet parent, Erie, Colorado
Market
U.S.A & Canada
U.S. & Canada Represent <20% of Worldwide Pet Dog Population. We have a large market opportunity with on average 500,000 dogs (U.S. and Canada) diagnosed with cancer each month.
According to the American Pet Products Association (APPA), in 2020 $103.6 billion was spent on pets in the U.S., with $42 billion being spent on pet food and treats [3].
Team
The team at Canine Biologics responsible for developing and reviewing our products holds 17 degrees including 6 Masters, 4 PhDs, 2 DVMs and over 175 years of total experience.
Jeff Sutherland
Founder, President & CEO
Mr. Sutherland is the founder of two pet food companies and has had a broad, international career with extensive experience in marketing, IT and management consulting. He also has significant Industry-specific experience in biotechnology, healthcare and finance.
He notes that, "Dogs and humans enjoy the most amazing cross-species relationship in the history of the planet! We want to honor that when they need our help the most. Given all they do for us and the lack of specific nutrition for dogs in the fight of their lives, we wanted to help them enjoy their highest quality of life."
Afshin Safavi
Chairman & Chief Science Officer
Dr. Afshin Safavi is a founder, consultant, board member, entrepreneur, and investor in biotech, animal health, pharma, IT, and real-estate. He holds a B.S. (Biochemistry) from UCLA, and a Ph.D. (Biochemistry) from Univ. of Kentucky Medical School.
Charles Mueller
Chief Financial Officer
Mr. Mueller is a former CFO for three companies specializing in manufacturing, software and the oil and gas industry, each with sales in excess of $200 million per annum.
Jennifer Brauns
North American Sales Director
Jennifer Brauns is a successful sales, marketing and media executive with more than 30 years of business experience. She founded Mile High Dog magazine in 2007 and was editor-in-chief and VP of sales and marketing. She has deep knowledge of canine health and nutrition.
Tim Bennett
Director & Acting Chief Marketing Officer
Tim served as General Director - Brand Strategy and Research for General Motors where he guided the global decision-making of GM's most senior leaders in brand portfolio management, including market entry planning, divestitures and capital planning. He is an associate professor of marketing and has guided significant marketing projects in over 20 countries.
Advisors
Dr. Korinn E. Saker
Veterinary Advisor
Dr. Saker is a full professor, Board-Certified Veterinary Nutritionist, PhD and researcher in oxidative stress diets for cancer and obesity.
Scott Hafeman
Veterinary Advisor
Dr. Hafeman is a practicing veterinarian who holds a PhD in Tumor Immunology and is an active practitioner who treats dogs with cancer on a daily basis.
Footnotes
Use of Proceeds
If the offering's maximum amount of $477,540 is raised:
| Use | Value | % of Proceeds |
|---|---|---|
| Compensation for managers | $125,000 | 26.2% |
| New product development | $25,000 | 5.2% |
| Crowd funding marketing | $15,000 | 3.1% |
| Inventory Purchases | $119,000 | 24.9% |
| Selling costs | $21,500 | 4.5% |
| Marketing Costs | $140,200 | 29.4% |
| Administrative Costs | $8,441 | 1.8% |
| Intermediary fees | $23,399 | 4.9% |
Terms
This is an offering of Common Shares, under registration exemption 4(a)(6), in Canine Life Sciences Inc, doing business as Canine Biologics. This offering must raise at least $10,000 by April 29, 2022 at 10:58am ET. If this offering doesn’t reach its target, then your money will be refunded. Canine Biologics may issue additional securities to raise up to $477,540, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
8,149,165 shares
×
$0.81 per share
$6,600,824implied valuation
Financials
Canine Biologics’ official name is Canine Life Sciences Inc, so that’s the name that appears in the statements below.
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
- Apr 29, 2022Primary offering finalized, selling shares
- Nov 19, 2021Greetings, We have great news. Our Liquid Diet...
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.